Emapalumab
Gamifant (emapalumab) is an antibody pharmaceutical. Emapalumab was first approved as Gamifant on 2018-11-20. It is used to treat hemophagocytic lymphohistiocytosis in the USA. The pharmaceutical is active against interferon gamma.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| hemic and lymphatic diseases | D006425 |
Trade Name
FDA
EMA
Gamifant
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Emapalumab
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Gamifant | emapalumab-lzsg | Orphan Medical | N-761107 RX | 2018-11-20 | 6 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| gamifant | Biologic Licensing Application | 2025-06-30 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hemophagocytic lymphohistiocytosis | — | D051359 | D76.1 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
emapalumab, Gamifant, Swedish Orphan Biovitrum AB (publ) | |||
| 2025-11-20 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9210 | Injection, emapalumab-lzsg, 1 mg |
Clinical
Clinical Trials
24 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemophagocytic lymphohistiocytosis | D051359 | — | D76.1 | — | 5 | 7 | 2 | 1 | 11 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Macrophage activation syndrome | D055501 | EFO_1001806 | — | — | 1 | 1 | — | — | 2 |
| Infections | D007239 | EFO_0000544 | — | — | 1 | 1 | — | — | 1 |
| Sars-cov-2 | D000086402 | — | — | — | 1 | 1 | — | — | 1 |
| Disease | D004194 | EFO_0000408 | R69 | — | — | 1 | — | — | 1 |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | — | — | 1 | — | — | 1 |
| Recurrence | D012008 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancytopenia | D010198 | — | D61.81 | — | 2 | — | — | — | 2 |
| Cytopenia | D000095542 | — | — | — | 2 | — | — | — | 2 |
| Graft rejection | D006084 | — | — | — | 1 | — | — | — | 1 |
| Juvenile arthritis | D001171 | EFO_1002007 | M08 | — | 1 | — | — | — | 1 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | — | 1 | — | — | — | 1 |
| Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
| Adult-onset still's disease | D016706 | EFO_0007135 | M06.1 | — | 1 | — | — | — | 1 |
| Granuloma | D006099 | — | — | 1 | 1 | — | — | — | 1 |
| Chronic granulomatous disease | D006105 | EFO_0000338 | D71 | 1 | 1 | — | — | — | 1 |
| Immune system diseases | D007154 | — | D89.9 | — | 1 | — | — | — | 1 |
Show 11 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rare diseases | D035583 | — | — | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
| Graft vs host disease | D006086 | — | D89.81 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Emapalumab |
| INN | elenbecestat |
| Description | Emapalumab, sold under the brand name Gamifant, is an anti-interferon-gamma (IFNγ) antibody medication used for the treatment of hemophagocytic lymphohistiocytosis (HLH), which has no cure.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1709815-23-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3989977 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB14724 |
| UNII ID | RXJ96XL94H (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 932 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
310 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use